Helios Bioactives
Methodology
We purchased seven Helios Bioactives products through normal retail channels between February and April 2026. Each was sent under blind labelling to an independent HPLC-MS lab in Utrecht.
Findings
| Product | Labelled | Measured | Verdict |
|---|---|---|---|
| Recovery 5mg | BPC-157 | 38% BPC-157 + unidentified peptide | Off-spec |
| Recovery 10mg | BPC-157 | 94% BPC-157 | On-spec |
| Cosmetic Renewal | Matrixyl 3000 | No peptide detected | Substituted |
The company declined repeated requests for a Certificate of Analysis covering the affected batches.